Self-Replicating RNA Vector Structure for Durable Vaccine Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current self-replicating mRNA (srRNA) vaccines face challenges in inducing long-term protective immunity due to short-term immune responses, necessitating improvements in vector structures such as 5' Cap structure, poly(A) tail length, and UTRs to enhance RNA production, stability, and translation efficiency.
Innovation Solution
Development of improved srRNA vectors with specific 5' Cap structures, 5' and 3' UTRs, and poly(A) tails, along with lipid nanoparticle compositions, to enhance in vivo expression time and immune response durability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of stationary object
If self-replicating mRNA vectors are used to enhance immune response durability, then the duration of action is improved, but the manufacturing precision of vector structures (5' Cap, poly(A) tail, UTRs) becomes more critical and complex
Solution Approach 1:
The patent applies parameter changes by optimizing specific structural parameters of the srRNA vector: extending the poly(A) tail to 100-200 nucleotides, modifying the 5' Cap structure to Cap1 or Cap2, and adjusting UTR lengths. These parameter modifications directly enhance the duration of immune response while managing the complexity of manufacturing precision through systematic optimization rather than trial-and-error
Solution Approach 2:
The patent applies local quality by making specific modifications to particular regions of the srRNA vector rather than uniformly changing the entire structure. The 5' Cap structure, 5' UTR, 3' UTR, and poly(A) tail are independently optimized with specific sequences and lengths tailored to their functional requirements, allowing precise control over translation efficiency, stability, and immune response duration
2Duration of action of stationary object
If poly(A) tail length is increased to enhance RNA stability and translation, then the duration of action is improved, but the manufacturing complexity increases
Solution Approach 1:
The patent systematically changes the poly(A) tail length parameter from conventional lengths to extended lengths of 100-200 nucleotides. This single parameter modification produces cumulative benefits for RNA stability, translation efficiency, and immune response durability without requiring complex structural changes elsewhere in the vector
Solution Approach 2:
The patent segments the vector optimization into independent modular components: the 5' Cap structure, 5' UTR, coding sequence, 3' UTR, and poly(A) tail. Each segment can be independently designed, synthesized, and optimized, reducing manufacturing complexity by allowing parallel development and testing of individual elements
3Productivity
If 5' Cap structure is modified to improve translation efficiency, then the productivity is improved, but the manufacturing precision requirements increase
Solution Approach 1:
The patent changes the 5' Cap structure parameter from the conventional Cap0 to Cap1 (with 2' O methylation at the first nucleotide) or Cap2 (with additional 2' O methylation). These well-defined chemical modifications can be reliably introduced during in vitro transcription using established enzymatic methods, improving translation efficiency without excessively increasing manufacturing precision requirements
Solution Approach 2:
The patent uses enzymatic capping systems as intermediaries to introduce modified Cap structures during in vitro transcription. Enzymes such as vaccinia virus capping enzyme and 2' O methyltransferases serve as mediators that reliably attach specific Cap structures to the transcript, reducing the need for complex post-transcriptional modification steps and simplifying manufacturing while ensuring precise Cap structure incorporation
Data Source
AI summary
The disclosure relates improved self-replicating RNA vectors e.g., for use as a RNA vaccine or therapeutic, and methods of use.